Company Filing History:
Years Active: 2005
Title: Shahzi Iqbal: Innovator in Gene Expression Technology
Introduction
Shahzi Iqbal is a notable inventor based in San Ramon, CA (US). He has made significant contributions to the field of gene expression technology. His work focuses on developing methods that can efficiently identify and isolate genes expressed in diseased versus normal tissues.
Latest Patents
Shahzi Iqbal holds a patent for a technology titled "Preferential Display." This invention addresses the pressing need for high throughput gene expression technology. It aims to identify and accurately isolate different genes expressed between diseased and normal tissues, which is crucial for discovering new drugs. The invention employs a combination of biomolecular chemistry methods to eliminate redundant sequences. It utilizes fluorescence dye assays to identify unique sequences from two cell or tissue populations. The process involves hybridizing cDNA from normal or diseased cells with the RNA of the complementary cells. The hybridized cDNA/RNA is then treated with exonucleases, leading to the degradation of all but the single-stranded RNA and DNA. Subsequently, RNA is eliminated using RNase, and the remaining unique DNA is amplified. This technique allows for the isolation of differentially expressed genes or gene fragments, providing a means to identify medium to low gene expressions that may otherwise be obscured.
Career Highlights
Shahzi Iqbal is associated with Genexpress Informatics, Inc., where he continues to innovate in the field of gene expression technology. His work has the potential to significantly impact drug discovery and development.
Collaborations
Shahzi Iqbal collaborates with Robert C Chin, enhancing the research and development efforts at Genexpress Informatics, Inc.
Conclusion
Shahzi Iqbal's contributions to gene expression technology exemplify the importance of innovation in the medical field. His patent for "Preferential Display" showcases his commitment to advancing scientific research and improving drug discovery processes.